Literature DB >> 27916195

Imaging features predict prognosis of patients with combined hepatocellular-cholangiocarcinoma.

Y Mao1, S Xu2, W Hu3, J Huang3, J Wang4, R Zhang5, S Li6.   

Abstract

AIM: To evaluate the prognostic value of imaging patterns in combined hepatocellular-cholangiocarcinoma.
MATERIALS AND METHODS: A total of 36 patients with histopathologically confirmed combined hepatocellular-cholangiocarcinoma were enrolled. Pretreatment imaging was conducted to evaluate the tumour enhancement patterns, based on which the disease was classified as two subtypes: radiographic hepatocellular carcinoma-dominant (n=26) and radiographic cholangiocarcinoma-dominant (n=10). Moreover, based on the proportion of components, all combined hepatocellular-cholangiocarcinoma cases were divided into histopathological hepatocellular carcinoma-dominant (n=26) or histopathological cholangiocarcinoma-dominant (n=10). The Kaplan-Meier method was used to compare patient outcome between the two subtypes of each classification. Univariate Cox regression analysis were employed to evaluate the prognostic relevance of the imaging and histopathological classification.
RESULTS: Consistency between histopathological and imaging classification was not high. Only 66.7% of patients had consistent classification. Moreover, the median overall survival of the radiographic cholangiocarcinoma-dominant and radiographic hepatocellular carcinoma-dominant population was 15.03 and 40.4 months, respectively (p=0.012); however, no significant difference was observed between histopathological type, with median overall survival being 32.07 and 40.4 months in the histopathological cholangiocarcinoma-dominant group and histopathological hepatocellular carcinoma-dominant group, respectively (p=0.784).
CONCLUSION: There was an association between imaging patterns and overall survival in combined hepatocellular-cholangiocarcinoma. Postoperative re-evaluation of imaging patterns could help to assess patient outcome.
Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27916195     DOI: 10.1016/j.crad.2016.11.003

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  5 in total

1.  How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

Authors:  Hong Seon Lee; Myeong-Jin Kim; Chansik An
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

2.  The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study.

Authors:  Chaobin He; Yize Mao; Jun Wang; Yunda Song; Xin Huang; Xiaojun Lin; Shengping Li
Journal:  J Gastrointest Surg       Date:  2018-04-17       Impact factor: 3.452

3.  Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas.

Authors:  Seung-Seob Kim; Sunyoung Lee; Jin-Young Choi; Joon Seok Lim; Mi-Suk Park; Myeong-Jin Kim
Journal:  Abdom Radiol (NY)       Date:  2020-11

4.  The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.

Authors:  Seong Kyun Na; Gwang Hyeon Choi; Han Chu Lee; Yong Moon Shin; Jihyun An; Danbi Lee; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

Review 5.  Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.

Authors:  Tae Hyung Kim; Haeryoung Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2020-07-27       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.